公开(公告)号：EP1913152A2

公开(公告)日：2008-04-23

申请号：EP06780670.3

申请日：2006-06-23

Applicant: Oncotherapy Science, Inc.

Inventor： NAKAMURA, Yusuke c/o Tht University Of Tokyo ,  FURUKAWA, Yoichi c/o The University Of Tokyo ,  HAMAMOTO, Ryuji c/o The University Of Tokyo ,  NAKATSURU, Shuichi c/o Oncotherapy Science, Inc.

IPC: C12Q1/48 ,  G01N33/68 ,  A61P35/00 ,  A61K38/00

CPC classification number: G01N33/5011 ,  C12Q1/48 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N2333/4736 ,  G01N2333/91011 ,  G01N2500/02

Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.

公开(公告)号：EP4367242A2

公开(公告)日：2024-05-15

申请号：EP22765643.6

申请日：2022-07-07

Applicant: Omega Therapeutics, Inc.

Inventor： NGUYEN, Laura Anh ,  FARELLI, Jeremiah D. ,  SCHEIDEGGER, Adam Walter ,  WITT, Abigail Elizabeth ,  CHEN, Justin ,  SULLIVAN, James Scott

IPC: C12N15/113 ,  C12N15/63 ,  C12N9/22 ,  C12N9/10 ,  C12N9/80 ,  A61K31/7088

CPC classification number: C12N15/113 ,  C12N9/22 ,  C12N2310/2020170501 ,  C07K2319/8120130101 ,  C12N15/63 ,  C12Y305/01098 ,  C12Y201/01043 ,  C12N9/80 ,  C12N9/1007

公开(公告)号：EP2714903B1

公开(公告)日：2018-03-21

申请号：EP12792440.5

申请日：2012-05-31

Applicant: OncoTherapy Science, Inc.

Inventor： HAMAMOTO, Ryuji ,  NAKAMURA, Yusuke ,  TSUNODA, Takuya

IPC: C12Q1/68 ,  C12N15/09 ,  A61K31/713 ,  A61K48/00 ,  A61P35/00 ,  C12N15/113 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/48 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57411 ,  G01N33/57423 ,  G01N33/57434 ,  G01N2500/04

Abstract: Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the SUV39H2 gene. The present invention further provides methods of screening for candidate substances useful in the treatment and/or prevention of an SUV39H2-associated cancer, such as lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor. The present invention further provides methods of inhibiting the cell growth and thereby treating or alleviating symptoms of an SUV39H2 associated cancer. The present invention also features double-stranded molecules against the SUV39H2 gene and vectors encoding thereof as well as compositions containing such components and their utility in connection with the treatment and prevention of an SUV39H2-associated cancer.

公开(公告)号：EP3194581A2

公开(公告)日：2017-07-26

申请号：EP15841324.5

申请日：2015-09-15

Applicant: Children's Medical Center Corporation

Inventor： ZHANG, Yi ,  MATOBA, Shogo

IPC: C12N9/02 ,  C12N5/075 ,  A01K67/027

CPC classification number: C12N15/877 ,  A01K67/0273 ,  A01K2227/105 ,  C12N5/0604 ,  C12N5/0606 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2517/04 ,  C12Y201/01043

Abstract: The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT) and the consequent production of nuclear transfer ESC (ntESC) and transgenic cells and/or non-human animals. More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of donor somatic cells prevents efficient somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of SCNT by exogenous or overexpression of the demethylase Kdm4 family and/or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases Suv39h1 and/or Suv39h2.

Abstract translation: 本发明提供了用于提高体细胞核转移（SCNT）效率和随后产生核转移ESC（ntESC）和转基因细胞和/或非人动物的方法和组合物。 更具体而言，本发明涉及在供体体细胞的核遗传物质中重编程耐受性区域（RRR）中组蛋白H3-赖氨酸9（H3K9me3）的三甲基化阻止有效体细胞核重编程或SCNT。 本发明提供了在通过外源或过表达脱甲基酶Kdm4家族和/或通过抑制组蛋白甲基转移酶Suv39h1和/或Suv39h2抑制H3K9me3的甲基化来提高SCNT功效的方法中减少H3K9me3的方法和组合物。

公开(公告)号：EP2970418A4

公开(公告)日：2016-08-17

申请号：EP14767620

申请日：2014-03-13

Applicant: DANA FARBER CANCER INST INC

Inventor： WALENSKY LOREN D

IPC: C07K14/47 ,  A61K38/17

CPC classification number: C12N9/96 ,  A61K38/00 ,  C07K14/47 ,  C12N9/1007 ,  C12Y201/01043

Abstract: Provided herein are polypeptides containing stabilized therapeutic peptides related to enhancer of zeste homolog 2 (EZH2), histone lysine N-methyltransferase. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.

Abstract translation: 本文提供含有与味精同系物2（EZH2），组蛋白赖氨酸N-甲基转移酶增强子相关的稳定治疗肽的多肽。 还提供含有这些多肽的组合物和使用这些肽在治疗癌症中的方法，其包括向受试者施用一种多肽。

公开(公告)号：EP3008183A1

公开(公告)日：2016-04-20

申请号：EP14729908.5

申请日：2014-06-13

Applicant: Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)

Inventor： ESTELLER BADOSA, Manel

IPC: C12N15/113 ,  A61K31/195 ,  C12Q1/68

CPC classification number: C12N15/1137 ,  A61K31/704 ,  A61K31/7105 ,  C12N15/1135 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043 ,  A61K2300/00

Abstract: The invention relates to the use of the amplification of SETDB1 gene in lung cancer patients as predictive marker for the determination of the response to a SETDB1 antagonist, particularly to a SETDB1 -specific RNAi or to mithramycin. The invention relates to methods of treatment, methods for predicting the clinical response to a SETDB1 antagonist and methods for selecting a lung cancer patient for being treated with a SETDB1 antagonist based on the detection of SETDB1 gene amplification.

公开(公告)号：EP2638163A4

公开(公告)日：2014-11-05

申请号：EP11840099

申请日：2011-11-12

Applicant: GEN HOSPITAL CORP

Inventor： LEE JEANNIE T ,  ZHAO JING ,  SARMA KAVITHA ,  BOROWSKY MARK ,  OHSUMI TOSHIRO KENDRICK

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs. d

Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如Polycomb Repressive Complex 2，抑制性核酸和用于靶向lncRNA的方法和组合物。

公开(公告)号：EP1599586B1

公开(公告)日：2011-04-06

申请号：EP04715568.4

申请日：2004-02-27

Applicant: Oncotherapy Science, Inc.

Inventor： NAKAMURA, Yusuke ,  FURUKAWA, Yoichi

IPC: C12N15/11

CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y201/01043

Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a ZNFN3A1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumer cell, for example liver or colon cancer cell, particularly HCC or colorectal adenocarcinoma.

公开(公告)号：EP1765994A2

公开(公告)日：2007-03-28

申请号：EP05804853.9

申请日：2005-05-27

Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Inventor： ZHANG, Yi ,  CAO, Ru

IPC: C12N9/10 ,  C12N5/10

CPC classification number: C12N9/1007 ,  C07K14/82 ,  C07K2319/20 ,  C12N2799/026 ,  C12Y201/01043 ,  G01N2333/91011

Abstract: The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.

公开(公告)号：EP1599586A2

公开(公告)日：2005-11-30

申请号：EP04715568.4

申请日：2004-02-27

Applicant: Oncotherapy Science, Inc. ,  The University of Tokyo

Inventor： NAKAMURA, Yusuke ,  FURUKAWA, Yoichi

IPC: C12N15/11

CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y201/01043

Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a ZNFN3A1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumer cell, for example liver or colon cancer cell, particularly HCC or colorectal adenocarcinoma.